Attorney Docket No.: 6511.204-US PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Polisetti et al. Confirmation No.: 3758

Application No.: 10/679,887 Group Art Unit: 1625

Filed: October 6, 2003 Examiner: Lambkin, Deborah C.

For: Aryl Carbonyl Derivatives as Therapeutic Agents

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Applicant(s) hereby submit __1__ sheet listing a reference and other information for consideration by the Examiner in accordance with 37 C.F.R. 1.56, 1.97, and 1.98:

INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application No.	10/679,887
				Filing Date	October 6, 2003
				Applicant	Polisetti et al.
				Art Unit	1625
				Examiner Name:	Lambkin, Deborah C.
Sheet	1	of	1	Atty. Docket No.	6511.204-US

U.S. PATENT DOCUMENTS

EXAMINER INITIALS	Cite No.	DOCUMENT NUMBER Number –Kind Code(if known)	Issue/Publication Date MM-DD-YYYY	NAME of Patentee or Applicant of Cited Document	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS

EXAMINER INITIALS	Cite No.	DOCUMENT NUMBER Number –Kind Code(if known)	Publication Date MM-DD-YYYY	NAME of Patentee or Applicant of Cited Document	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	T
		WO 01/00206	04/01/01	Daiichi Pharm.		

EXAMINER SIGNATURE		DATE CONSIDERED	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application No.	10/679,887
				Filing Date	October 6, 2003
				Applicant	Polisetti et al.
				Art Unit	1625
				Examiner Name:	To be assigned
Sheet		of		Atty. Docket No.	6511.204-US

NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T

EXAMINER SIGNATURE		DATE CONSIDERED	

Except for US patent documents, a copy of each listed reference is enclosed or submitted herewith.

Copyrighted material submitted with this Information Disclosure Statement may be delivered to the Government under license from the Copyright Clearance Center, Inc., or other rights holders – no further reproduction of such works is permitted.

Inclusion of any reference is not intended to constitute an admission that the reference is "prior art" unless it is specifically designated as such.

This information disclosure statement is being filed **after** the mailing date of any of a final action under 37 C.F.R. § 1.113, a notice of allowance under 37 C.F.R. § 1.311, or an action that otherwise closes prosecution, but before, or simultaneously with, the payment of the issue fee.

Accompanying this information disclosure statement is the fee set forth in § 1.17(p) (currently $180.00). The Examiner is hereby authorized to charge Deposit Account No. 14-1447 in the amount of $180.00. Applicants respectfully requests that any reference or other information listed above be made of record in this patent application. The Examiner is invited to call the undersigned if there are any questions concerning this submission or application.

Respectfully submitted,

Date: August 29, 2007

/ Rosemarie R. Wilk-Orescan; Reg. No. 45,220 /

Rosemarie R. Wilk-Orescan
Reg. No. 45,220
Novo Nordisk Inc.
100 College Road West
Princeton, NJ 08540
(609) 987-5800

Use the following customer number for all correspondence regarding this application.

23650

PATENT TRADEMARK OFFICE